Composition: Suspension in a hydro-repellent vehicle. Contains Domperidone 6 g. Excipient c.s.p.100ml.
Therapeutic action: DOMPERGO is a selective dopaminergic antagonist of D 2 receptors
Indications: It is indicated in:
A) Prophylaxis and treatment of alkaloid poisoning derived from Indol (or ergo alkaloids) (E +). Routine management of pastures consociated with natural rye grass or fescue exposes equines to a considerable load of this type of mycotoxins, produced (biosynthesized) by symbiotic endophytes in the first case, produced by Neotyphodium lolii, and in fescue, by the Neotyphodium Coenophialum or other parasitic fungus of the spikes (Claviceps sp), in other grasses. The amount and quality of alkaloid produced depends on environmental factors (drought, humidity, temperature, etc.), soil type, management culture (on grazing, competition with other grasses, fertilization, sowing time, etc.) variables of each animal of the population.
These substances indole alkaloids produce a number of clinical signs in different species. The mare affects the reproductive mat in its different stages presenting as agalactia, placental abnormalities, lengthening of births, resorptions, lack of zeal among other signs. In the pregnant foal there are also numerous pathologies including respiratory failure, osteoarticular alterations, decreased serum immunoglobulin and perinatal death.
Signs on the foal (mainly osteoarticular) once established can not be reversed, therefore DOMPERGO is indicated mainly as a prophylactic or therapeutic measure of the mare exposed to this mycotoxin. Thus it can be summarized:
1) DOMPERGO should be administered 35 days prior to the probable date of delivery. Treatment will be continued until the day of delivery, which usually occurs on or before the estimated date. If there is no delivery in the pre-established period, after 7 days after that date, discontinue treatment. If, on the other hand, childbirth occurs according to the prediction, colostrum and milk production tend to be normal or abundant.
If necessary, the treatment can be sustained according to the veterinary medical criteria.
2) DOMPERGO is indicated in mares that initiate lactation with decrease or absence of milk production. Treatment should be maintained according to the clinical picture and professional judgment, but generally it is not necessary to extend it for more than 20 days.
3) DQMPERGO is also given in mares that show signs of low ovarian activity. In general, ovarian follicular growth and ovulation occur after 15 to 17 days of initiation of treatment, and should be evaluated by touch.
Once delivered, treatment may be required for the first 60 days to maintain the primary corpus luteum, until progesterone production from accessory luteal bodies, which are dependent on chorionic gonadotrophin (day 35-50), begins.
It is a complementary method of aiding the analysis of blood hormones (progesterone and estrogens), since concomitant treatment with synthetic progesterone may be required. In case of consumption by the pregnant mare of grasses with toxins, prior to the administration of DOMPERGO, this does not normalize the existence of defects (especially osteoarticular) in the fetus.
B) DOMPERGO is indicated as an inducer of dairy production, mainly in filth with low milk production, whose cause is not the intoxication mentioned. The duration of treatment depends on the judgment of the practitioner, but generally does not need to be extended beyond 20 days.
The main clinical utility of domperidone in other species and in humans has been its application as normocinetic and antiemetic. Although this function does not have direct application in the equine, it has shown great potential of both clinical and experimental use in gastrointestinal surgery, since its adequate administration, it avoids the ilio post-operative. Its effects are centered on the mechanical and functional restoration of peristaltic gastro-duodenal evacuation coordination.
Route of administration: Oral route. No prior preparation required. It is presented in a dosi fi er for direct use.
Dosage: The clinically established dose of domperidone for horses is 1.1 mg per kilogram live weight, with no difference in age or sex. It is convenient to administer before the ration. DOMPERGO has a potency of 60 mg / ml. Its graduated dispenser contains 40 ml (1 ml = 55 kgpv) and has a locking system every 10 ml (10 ml = 600 mg), with a dose of 550 ml for an equine of 550 kg (routine dose). In total, each injector provides 4 routine doses (2400 mg = 2200 kgpv). DDMPERGO is administered every 24 hours.
Intermediates of medication, side effects and contraindications:
DOMPERGO, has a high safety margin at the recommended dosage and frequency. It is important to clarify that in states where high levels of bioavailability are required, it is advisable to administer up to 6 times the therapeutic dose to overcome the strong retention of enterohepatic metabolism (first-pass metabolism). This is not found in horses.
Concomitant administration of anticholinergic medicinal products may counteract the action of domperidone. Atropine should not be administered together with DOMPERGO.
The normokinetic action of the drug may influence the bioavailability of other drugs, but at the usual doses this effect is negligible.
Although the metabolic pathway in the equine is not described, CYP3A4 inhibitors, cytochrome P 450 sub-group, such as azole group antitumor (ketoconazole), macrolide antibiotics (erythromycin, clarithromycin or azithromycin) inhibitory protease drugs (saquinavir, ritonavir, iopinavir and others) and nefazodone modi fi ed the bioavailability of domperidone, increasing its C almost triple in experimental animals and in humans.
Precautions: Equines treated may be maintained on pasture and / or green, although avoid excessive consumption of fiber, not to promote the acceleration of intestinal transit since its kinetic activity is promoted by medication.
Administered at the recommended dosage and frequency, there is no toxicity. DOMPERGO, should not be administered to humans or to any animal species that is not expressly indicated.
Presentation: Syringe with gradual dispenser of 40 ml.